Codexis, Inc. (CDXS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Codexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing high-performance enzymes and proteins using its proprietary CodeEvolver directed evolution technology. The company operates in two primary areas: pharma biocatalysis for small molecule therapeutics and the Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform for RNAi therapeutics. As of November 3, 2025, there were approximately 90.3 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $8,601 | $12,833 | $31,472 | $37,885 |
| Net Loss | $(19,615) | $(20,640) | $(53,575) | $(54,900) |
| Net Loss Per Share (Basic/Diluted) | $(0.22) | $(0.29) | $(0.62) | $(0.78) |
| Product Gross Margin | 64% | 61% | 64% | 53% |
| Cash & Cash Equivalents | $25,351 | $37,452 | $25,351 | $37,452 |
| Short-term Investments | $33,350 | $52,800 | $33,350 | $52,800 |
| Long-term Debt (Carrying Value) | $39,729 | $28,905 | $39,729 | $28,905 |
| Working Capital | $57,717 | $75,124 | $57,717 | $75,124 |
Note: Cash flow from operating activities for the nine months ended September 30, 2025, was a net use of $39.5 million.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 33% year-over-year in Q3 2025 and 17% for the nine-month period. Product revenue dropped 39% in Q3 and 25% for the nine months, primarily due to variability in customer manufacturing schedules and clinical trial timing. R&D revenue increased slightly (7% in Q3, 3% for 9M) due to higher collaboration fees, partially offset by the non-recurrence of a $6.0 million milestone from Roche Sequencing Solutions in Q1 2024.
- Expense Management: Total operating expenses decreased 6% for the nine months ended September 30, 2025. Selling, General, and Administrative (SG&A) expenses declined 15% due to lower stock-based compensation and legal costs. Research and Development (R&D) expenses increased 19% due to higher employee-related costs and lab supplies.
- Debt Financing: Long-term debt increased significantly due to the funding of the second tranche ($10.0 million) of the Innovatus Loan in June 2025, bringing the total principal to $40.0 million. The effective interest rate on this loan is 12.7%.
- Equity Issuance: The company raised $16.4 million in net proceeds from the sale of common stock under its Cantor Sales Agreement during the nine months ended September 30, 2025.
Outlook, Risks, and Unusual Items
- Subsequent Events (Post-Sept 30, 2025):
- Merck Agreement: In October 2025, Codexis entered into an enzyme supply assurance agreement with Merck Sharp & Dohme LLC, entitling the company to a one-time non-refundable payment of $37.8 million, expected to be received in Q4 2025.
- Workforce Reduction: On November 6, 2025, the company announced a workforce reduction of approximately 24% to streamline operations and focus on the ECO Synthesis platform. This is expected to result in an additional expense of approximately $3.5 million recognized in Q4 2025.
- Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($58.7 million total) combined with future revenues will provide adequate funds for at least the next 12 months. However, the company may need additional capital if plans change.
- Risks: Key risks include dependence on a limited number of customers (Customer G accounted for 40% of Q3 revenue), reliance on third-party contract manufacturers, the unproven nature of the ECO Synthesis platform at commercial scale, and potential regulatory challenges regarding enzyme products.
Investor Verification Checklist
- Merck Payment Timing: Verify the receipt of the $37.8 million payment from Merck in Q4 2025 and its impact on cash flow and revenue recognition.
- Restructuring Costs: Monitor the actual costs associated with the 24% workforce reduction announced in November 2025 against the estimated $3.5 million expense.
- Debt Covenants: Review compliance with the Innovatus Loan covenants, specifically liquidity and net product revenue thresholds, given the recent revenue declines.
- Customer Concentration: Assess the risk associated with Customer G, which represented 40% of Q3 2025 revenue, and the stability of supply agreements with top customers.
- ECO Synthesis Progress: Track the commercialization milestones and partnership announcements regarding the ECO Synthesis platform for RNAi therapeutics.